MET inhibitors for treatment of advanced hepatocellular carcinoma: A review

doi:10.3748/wjg.v21.i18.5445

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (10474)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

616

WORD

244

HTML

5500

Tables (1-3)

276

Sum=6636

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

587

Download

1205

Sum=1792

Publishing Process of This Article

Item

Count

Browse

1005

Download

1041

Sum=2046

May 14, 2015 (publication date) through Dec 2, 2024

Times Cited of This Article

Times Cited (52)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. May 14, 2015; 21(18): 5445-5453
Published online May 14, 2015. doi: 10.3748/wjg.v21.i18.5445

Table 3 Current status of MET inhibitors for the treatment of advanced hepatocellular carcinoma

First-line therapy of advanced HCC

INC280: A phase II sing-arm trial (NCT01737827)

MSC2156119J vs sorafenib: A phase II RCT (NCT01988493)

Golvatinib plus sorafenib vs sorafenib alone: A phase II RCT (NCT01271504)

Foretinib: A phase II sing-arm trial (NCT00920192)

Second-line therapy of advanced HCC

Tivantinib vs placebo: A phase II RCT (NCT00988741)

Tivantinib vs placebo: A phase III RCT (NCT01755767)

Cabozantinib vs placebo: A phase II randomized discontinuation trial (NCT00940225)

Cabozantinib vs placebo: A phase III RCT (NCT01908426)

INC280 vs placebo: A phase II RCT (NCT01964235)

MSC2156119J: A phase II sing-arm trial (NCT02115373)

HCC: Hepatocellular carcinoma.

Citation: Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 2015; 21(18): 5445-5453
URL: https://www.wjgnet.com/1007-9327/full/v21/i18/5445.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i18.5445